title: Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients.
abstract: This study aimed to clarify the association between the TP53 rs1625895 polymorphism and the efficiency of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy in 106 patients with diffuse large B cell lymphoma (DLBCL). All patients received six to eight courses of R-CHOP therapy as a first-line treatment. The rs1625895 polymorphism was genotyped by polymerase chain reaction with restriction fragment length polymorphism assay. The G/G genotype of the TP53 rs1625895 polymorphism was shown to be associated with a high probability of R-CHOP therapy failure in DLBCL patients according to the probability of remission as well as 5-year overall and relapse-free survivals.
authors.affiliation: Institute of Internal and Preventive Medicine, Siberian Branch, Russian Academy of Medical Sciences, Novosibirsk, Russia.
authors.forename: Elena N
authors.initials: EN
authors.lastname: Voropaeva
authors.forename: Mikhail I
authors.initials: MI
authors.lastname: Voevoda
authors.forename: Tatiana I
authors.initials: TI
authors.lastname: Pospelova
authors.forename: Vladimir N
authors.initials: VN
authors.lastname: Maksimov
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D008297:Male; D011110:Polymorphism, Genetic; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: TP53 gene; immunotherapy; non-Hodgkin lymphoma; prognostic factors